0000000000431185

AUTHOR

J.m. Montserrat

showing 4 related works from this author

Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea : data from t…

2020

Background and aim: Obstructive sleep apnea (OSA) is an independent risk factor for dyslipidemia. The current study examined the effects of positive airway pressure (PAP) treatment on lipid status in the European Sleep Apnea Database (ESADA). Methods: The prospective cohort study enrolled 1564 OSA subjects (74% male, mean age 54 ± 11y, body mass index (BMI) 32.7 ± 6.6 kg/m2 and apnea-hypopnea index (AHI) 40.3 ± 24.4 n/h) undergoing PAP therapy for at least three months (mean 377.6 ± 419.5 days). Baseline and follow-up total cholesterol (TC) from nine centers were analyzed. Repeated measures and logistic regression tests (adjusted for age, sex, weight changes, lipid lowering medication, PAP …

cardiovascular riskAdultMalemedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioPositive airway pressure03 medical and health sciences0302 clinical medicineInternal medicinePositive airway pressuremedicineCardiovascular risk Cholesterol Hypoxia Sleep apneaHumanspositive airway pressureProspective StudiesRisk factorProspective cohort studyHypoxiaAgedSleep Apnea ObstructiveFramingham Risk ScoreContinuous Positive Airway Pressurebusiness.industryhypoxiaSleep apneaSleep apneacholesterolGeneral MedicineMiddle Agedmedicine.diseasesleep apneaCardiovascular riskObstructive sleep apneaCardiovascular risk ; Cholesterol ; Hypoxia ; Positive airway pressure ; Sleep apnea.Cholesterol030228 respiratory systemPatient ComplianceFemaleHuman medicinebusinessBody mass index030217 neurology & neurosurgeryDyslipidemiaSleep medicine
researchProduct

Adipose tissue in obesity and obstructive sleep apnoea

2011

A European Respiratory Society research seminar on ‘‘Metabolic alterations in obstructive sleep apnoea (OSA)’’ was jointly organised in October 2009 together with two EU COST actions (Cardiovascular risk in the obstructive sleep apnoea syndrome, action B26, and Adipose tissue and the metabolic syndrome, action BM0602) in order to discuss the interactions between obesity and OSA. Such interactions can be particularly significant in the pathogenesis of metabolic abnormalities and in increased cardiovascular risk in OSA patients. However, studying the respective role of OSA and obesity is difficult in patients, making it necessary to refer to animal models or in vitro systems. Since most OSA p…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyLipoxygenaseAdipose tissueMiceInsulin resistancestomatognathic systemAnimalsHumansMedicineObesityHypoxiaIntensive care medicineDyslipidemiasInflammationSleep Apnea Obstructivebusiness.industryAdipocyte dyslipidaemia hypoxia liver dysfunction obesitySleep apneaHypoxia (medical)medicine.diseaseObesitySleep in non-human animalsRatsnervous system diseasesrespiratory tract diseasesOxidative StressAdipose TissuePhysical therapyFemaleInsulin ResistanceLiver dysfunctionMetabolic syndromemedicine.symptombusinessEuropean Respiratory Journal
researchProduct

THE EUROPEAN SLEEP APNOEA DATABASE (ESADA) -- Report from 22 European Sleep Laboratories

2011

The European Sleep Apnoea Database (ESADA) reflects a network of 22 sleep disorder centres in Europe enabled by a COST action B26 programme. This ongoing project aims to describe differences in standard clinical care of patients with obstructive sleep apnoea (OSA) and to establish a resource for genetic research in this disorder. Patients with suspected OSA are consecutively included and followed up according to local clinical standards. Anthropometrics, medical history, medication, daytime symptoms and sleep data (polysomnography or cardiorespiratory polygraphy) are recorded in a structured web-based report form. 5,103 patients (1,426 females, mean±SD age 51.8±12.6 yrs, 79.4% with apnoea/h…

Pulmonary and Respiratory MedicineAdultMalePediatricsmedicine.medical_specialtyAdolescentDatabases FactualCross-sectional studyPolysomnographyComorbidityCohort StudiesSleep Apnea SyndromesRisk FactorsSurveys and QuestionnairesmedicineHumansMedical historyRespiratory systemAgedSleep disordermedicine.diagnostic_testAnthropometryModels Geneticbusiness.industrycomorbidity European Sleep Apnoea Database genetic multicentre cohort obstructive sleep apnoea syndromeCardiorespiratory fitnessMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREAnthropometryMiddle Agedmedicine.diseaserespiratory tract diseasesObesity MorbidEuropeCohortFemaleHuman medicinebusiness
researchProduct

Obstructive sleep apnoea in adult patients post-tonsillectomy

2021

Background: The impact of removing the upper airway lymphoid tissue and in particular, tonsillectomy, in adults with OSA has not been demonstrated in large populations. Aims: To compare the severity of OSA and the prevalence of cardiovascular, metabolic and respiratory co-morbidities between patients with OSA who had undergone previous tonsillectomy and those who had not. Methods: The 19,711 participants in this study came from the European sleep apnea database (ESADA) which comprises data from unselected adult patients aged 18–80 years with a history of symptoms suggestive of OSA referred to sleep centers throughout Europe. Results: There were no differences between the two groups in terms…

AdultPediatricsmedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]ESADALymphoid tissue overgrowthSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesSleep apnoea0302 clinical medicinemedicineHumansMass indexRespiratory systemTonsillectomySleep Apnea ObstructiveAdult patientsbusiness.industrySleep apneaGeneral MedicineESADA ; Lymphoid tissue overgrowth ; Sleep apnoea ; Tonsillectomy.medicine.diseaseSleep in non-human animalsrespiratory tract diseasesTonsillectomy[SDV] Life Sciences [q-bio]Europe030228 respiratory systemDiabetes Mellitus Type 2Lower prevalenceTonsillectomy.AirwaybusinessSleep030217 neurology & neurosurgery
researchProduct